{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T04:04:21Z","timestamp":1744689861808,"version":"3.40.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Special Clinical Research Project of Shanghai Municipal Health Commission","award":["202240325"],"award-info":[{"award-number":["202240325"]}]},{"name":"Key Discipline Development Project of the Shanghai Municipal Health System","award":["2024ZDXK0047"],"award-info":[{"award-number":["2024ZDXK0047"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-025-06168-z","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T06:51:15Z","timestamp":1742539875000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Elevated VRK1 levels after androgen deprivation therapy promote prostate cancer progression by upregulating YAP1 expression"],"prefix":"10.1007","volume":"151","author":[{"given":"Yibo","family":"Meng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianchao","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hangbin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenchen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinghao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuetao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaozong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xilong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guowei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wandong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"issue":"1","key":"6168_CR1","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.molcel.2016.09.012","volume":"64","author":"H Aihara","year":"2016","unstructured":"Aihara H, Nakagawa T, Mizusaki H, Yoneda M, Kato M, Doiguchi M, Imamura Y, Higashi M, Ikura T, Hayashi T, Kodama Y, Oki M, Nakayama T, Cheung E, Aburatani H, Takayama K-I, Koseki H, Inoue S, Takeshima Y, Ito T (2016) Histone H2A T120 phosphorylation promotes oncogenic transformation via upregulation of cyclin D1. Mol Cell 64(1):176\u2013188. https:\/\/doi.org\/10.1016\/j.molcel.2016.09.012","journal-title":"Mol Cell"},{"issue":"11","key":"6168_CR2","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Luo J (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. New Engl J Med 371(11):1028\u20131038. https:\/\/doi.org\/10.1056\/NEJMoa1315815","journal-title":"New Engl J Med"},{"issue":"6","key":"6168_CR3","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.cell.2013.11.012","volume":"155","author":"VK Arora","year":"2013","unstructured":"Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis C, Zheng D, Sawyers CL (2013) Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 155(6):1309\u20131322. https:\/\/doi.org\/10.1016\/j.cell.2013.11.012","journal-title":"Cell"},{"issue":"12","key":"6168_CR4","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/nrurol.2016.212","volume":"13","author":"G Attard","year":"2016","unstructured":"Attard G, Antonarakis ES (2016) Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide. Nat Rev Urol 13(12):697\u2013698. https:\/\/doi.org\/10.1038\/nrurol.2016.212","journal-title":"Nat Rev Urol"},{"issue":"7","key":"6168_CR5","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1158\/1541-7786.MCR-12-0116","volume":"10","author":"GS Baia","year":"2012","unstructured":"Baia GS, Caballero OL, Orr BA, Lal A, Ho JSY, Cowdrey C, Tihan T, Mawrin C, Riggins GJ (2012) Yes-associated protein 1 is activated and functions as an oncogene in meningiomas. Mol Cancer Res 10(7):904\u2013913. https:\/\/doi.org\/10.1158\/1541-7786.MCR-12-0116","journal-title":"Mol Cancer Res"},{"key":"6168_CR6","doi-asserted-by":"publisher","first-page":"e00499","DOI":"10.7554\/eLife.00499","volume":"2","author":"MD Balbas","year":"2013","unstructured":"Balbas MD, Evans MJ, Hosfield DJ, Wongvipat J, Arora VK, Watson PA, Chen Y, Greene GL, Shen Y, Sawyers CL (2013) Overcoming mutation-based resistance to antiandrogens with rational drug design. eLife 2:e00499. https:\/\/doi.org\/10.7554\/eLife.00499","journal-title":"eLife"},{"issue":"1","key":"6168_CR7","doi-asserted-by":"publisher","first-page":"6411","DOI":"10.1038\/ncomms7411","volume":"6","author":"U Basu-Roy","year":"2015","unstructured":"Basu-Roy U, Bayin NS, Rattanakorn K, Han E, Placantonakis DG, Mansukhani A, Basilico C (2015) Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells. Nat Commun 6(1):6411. https:\/\/doi.org\/10.1038\/ncomms7411","journal-title":"Nat Commun"},{"issue":"5","key":"6168_CR8","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim C-S, Kimura G, Mainwaring P, Mansbach H, Investigators PREVAIL (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371(5):424\u2013433. https:\/\/doi.org\/10.1056\/NEJMoa1405095","journal-title":"N Engl J Med"},{"issue":"11","key":"6168_CR9","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1158\/1078-0432.CCR-13-3309","volume":"20","author":"H Beltran","year":"2014","unstructured":"Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, Huang J, True L, Gleave ME, Soule H, Logothetis C, Rubin MA (2014) Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res 20(11):2846\u20132850. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-3309","journal-title":"Clin Cancer Res"},{"issue":"1","key":"6168_CR10","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.prp.2017.10.014","volume":"214","author":"Z Ben","year":"2018","unstructured":"Ben Z, Gong L, Qiu Y (2018) High expression of VRK1 is related to poor prognosis in glioma. Pathol Res Pract 214(1):112\u2013118. https:\/\/doi.org\/10.1016\/j.prp.2017.10.014","journal-title":"Pathol Res Pract"},{"issue":"4","key":"6168_CR11","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ccell.2017.09.003","volume":"32","author":"EG Bluemn","year":"2017","unstructured":"Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, Bianchi-Frias D, Dumpit RF, Kaipainen A, Corella AN, Yang YC, Nyquist MD, Mostaghel E, Hsieh AC, Zhang X, Corey E, Brown LG, Nguyen HM, Pienta K, Nelson PS (2017) Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell 32(4):474\u2013489. https:\/\/doi.org\/10.1016\/j.ccell.2017.09.003","journal-title":"Cancer Cell"},{"issue":"23","key":"6168_CR12","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.cub.2007.10.039","volume":"17","author":"FD Camargo","year":"2007","unstructured":"Camargo FD, Gokhale S, Johnnidis JB, Fu D, Bell GW, Jaenisch R, Brummelkamp TR (2007) YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol 17(23):2054\u20132060. https:\/\/doi.org\/10.1016\/j.cub.2007.10.039","journal-title":"Curr Biol"},{"issue":"1","key":"6168_CR13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41698-024-00667-x","volume":"8","author":"S Cheng","year":"2024","unstructured":"Cheng S, Li L, Yeh Y, Shi Y, Franco O, Corey E, Yu X (2024) Unveiling novel double-negative prostate cancer subtypes through single-cell RNA sequencing analysis. Npj Precis Oncol 8(1):171. https:\/\/doi.org\/10.1038\/s41698-024-00667-x","journal-title":"Npj Precis Oncol"},{"issue":"12","key":"6168_CR14","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1038\/onc.2015.219","volume":"35","author":"E Ciamporcero","year":"2016","unstructured":"Ciamporcero E, Shen H, Ramakrishnan S, YuKu S, Chintala S, Shen L, Adelaiye R, Miles KM, Ullio C, Pizzimenti S, Daga M, Azabdaftari G, Attwood K, Johnson C, Zhang J, Barrera G, Pili R (2016) YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage. Oncogene 35(12):1541\u20131553. https:\/\/doi.org\/10.1038\/onc.2015.219","journal-title":"Oncogene"},{"issue":"21","key":"6168_CR15","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS De Bono","year":"2011","unstructured":"De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Scher HI (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995\u20132005. https:\/\/doi.org\/10.1056\/NEJMoa1014618","journal-title":"N Engl J Med"},{"issue":"6","key":"6168_CR16","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.cell.2007.07.019","volume":"130","author":"J Dong","year":"2007","unstructured":"Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, Gayyed MF, Anders RA, Maitra A, Pan D (2007) Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 130(6):1120\u20131133. https:\/\/doi.org\/10.1016\/j.cell.2007.07.019","journal-title":"Cell"},{"issue":"1","key":"6168_CR17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.eururo.2014.05.005","volume":"67","author":"E Efstathiou","year":"2015","unstructured":"Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, Tu SM, Aparicio A, Troncoso P, Mohler J, Logothetis CJ (2015) Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol 67(1):53\u201360. https:\/\/doi.org\/10.1016\/j.eururo.2014.05.005","journal-title":"Eur Urol"},{"issue":"4","key":"6168_CR18","doi-asserted-by":"publisher","first-page":"405","DOI":"10.20892\/j.issn.2095-3941.2017.0083","volume":"14","author":"KC Filiz","year":"2017","unstructured":"Filiz KC, Ummuhan D, Seyma O, Esra K, Pinar EZ (2017) Increased expression of YAP1 in prostate cancer correlates with extraprostatic extension. Cancer Biol Med 14(4):405. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2017.0083","journal-title":"Cancer Biol Med"},{"issue":"9","key":"6168_CR19","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.ajpath.2023.05.013","volume":"193","author":"F Handle","year":"2023","unstructured":"Handle F, Puhr M, Gruber M, Andolfi C, Sch\u00e4fer G, Klocker H, Haybaeck J, De Wulf P, Culig Z (2023) The Oncogenic protein kinase\/ATPase RIOK1 is up-regulated via the c-myc\/E2F transcription factor axis in prostate cancer. Am J Pathol 193(9):1284\u20131297. https:\/\/doi.org\/10.1016\/j.ajpath.2023.05.013","journal-title":"Am J Pathol"},{"issue":"4","key":"6168_CR20","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/nrc3458","volume":"13","author":"KF Harvey","year":"2013","unstructured":"Harvey KF, Zhang X, Thomas DM (2013) The Hippo pathway and human cancer. Nat Rev Cancer 13(4):246\u2013257. https:\/\/doi.org\/10.1038\/nrc3458","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"6168_CR21","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0002-9440(10)63112-4","volume":"164","author":"J Holzbeierlein","year":"2004","unstructured":"Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P, Reuter V, Gerald WL (2004) Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 164(1):217\u2013227. https:\/\/doi.org\/10.1016\/S0002-9440(10)63112-4","journal-title":"Am J Pathol"},{"issue":"3","key":"6168_CR22","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1091\/mbc.E12-06-0456","volume":"24","author":"M-W Jeong","year":"2013","unstructured":"Jeong M-W, Kang T-H, Kim W, Choi YH, Kim K-T (2013) Mitogen-activated protein kinase phosphatase 2 regulates histone H3 phosphorylation via interaction with vaccinia-related kinase 1. Mol Biol Cell 24(3):373\u2013384. https:\/\/doi.org\/10.1091\/mbc.E12-06-0456","journal-title":"Mol Biol Cell"},{"issue":"21","key":"6168_CR23","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1038\/onc.2014.206","volume":"34","author":"N Jiang","year":"2015","unstructured":"Jiang N, Hjorth-Jensen K, Hekmat O, Iglesias-Gato D, Kruse T, Wang C, Wei W, Ke B, Yan B, Niu Y, Olsen JV, Flores-Morales A (2015) In vivo quantitative phosphoproteomic profiling identifies novel regulators of castration-resistant prostate cancer growth. Oncogene 34(21):2764\u20132776. https:\/\/doi.org\/10.1038\/onc.2014.206","journal-title":"Oncogene"},{"issue":"24","key":"6168_CR24","doi-asserted-by":"publisher","first-page":"8533","DOI":"10.1128\/MCB.00018-07","volume":"27","author":"T-H Kang","year":"2007","unstructured":"Kang T-H, Park D-Y, Choi YH, Kim K-J, Yoon HS, Kim K-T (2007) Mitotic histone H3 phosphorylation by vaccinia-related kinase 1 in mammalian cells. Mol Cell Biol 27(24):8533\u20138546. https:\/\/doi.org\/10.1128\/MCB.00018-07","journal-title":"Mol Cell Biol"},{"issue":"18","key":"6168_CR25","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1242\/jcs.026757","volume":"121","author":"T-H Kang","year":"2008","unstructured":"Kang T-H, Park D-Y, Kim W, Kim K-T (2008) VRK1 phosphorylates CREB and mediates CCND1 expression. J Cell Sci 121(18):3035\u20133041. https:\/\/doi.org\/10.1242\/jcs.026757","journal-title":"J Cell Sci"},{"key":"6168_CR26","doi-asserted-by":"publisher","first-page":"8126","DOI":"10.1038\/ncomms9126","volume":"6","author":"G Kuser-Abali","year":"2015","unstructured":"Kuser-Abali G, Alptekin A, Lewis M, Garraway IP, Cinar B (2015) YAP1 and AR interactions contribute to the switch from androgen-dependent to castration-resistant growth in prostate cancer. Nat Commun 6:8126. https:\/\/doi.org\/10.1038\/ncomms9126","journal-title":"Nat Commun"},{"issue":"13","key":"6168_CR27","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1038\/s41388-021-01718-4","volume":"40","author":"H-C Lee","year":"2021","unstructured":"Lee H-C, Ou C-H, Huang Y-C, Hou P-C, Creighton CJ, Lin Y-S, Hu C-Y, Lin S-C (2021) YAP1 overexpression contributes to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer. Oncogene 40(13):2407\u20132421. https:\/\/doi.org\/10.1038\/s41388-021-01718-4","journal-title":"Oncogene"},{"issue":"D1","key":"6168_CR28","doi-asserted-by":"publisher","first-page":"D1211","DOI":"10.1093\/nar\/gky869","volume":"47","author":"J Ma","year":"2019","unstructured":"Ma J, Chen T, Wu S, Yang C, Bai M, Shu K, Li K, Zhang G, Jin Z, He F, Hermjakob H, Zhu Y (2019) iProX: an integrated proteome resource. Nucleic Acids Res 47(D1):D1211\u2013D1217. https:\/\/doi.org\/10.1093\/nar\/gky869","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"6168_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0203397","volume":"13","author":"AM Mon","year":"2018","unstructured":"Mon AM, MacKinnon AC, Traktman P (2018) Overexpression of the VRK1 kinase, which is associated with breast cancer, induces a mesenchymal to epithelial transition in mammary epithelial cells. PLoS ONE 13(9):e0203397. https:\/\/doi.org\/10.1371\/journal.pone.0203397","journal-title":"PLoS ONE"},{"issue":"14","key":"6168_CR30","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1007\/s00018-018-2746-7","volume":"75","author":"DS Moura","year":"2018","unstructured":"Moura DS, Campillo-Marcos I, V\u00e1zquez-Cedeira M, Lazo PA (2018) VRK1 and AURKB form a complex that cross inhibit their kinase activity and the phosphorylation of histone H3 in the progression of mitosis. Cell Mol Life Sci CMLS 75(14):2591\u20132611. https:\/\/doi.org\/10.1007\/s00018-018-2746-7","journal-title":"Cell Mol Life Sci CMLS"},{"issue":"46","key":"6168_CR31","doi-asserted-by":"publisher","first-page":"6718","DOI":"10.1038\/sj.onc.1204889","volume":"20","author":"S Mousses","year":"2001","unstructured":"Mousses S, Wagner U, Chen Y, Kim JW, Bubendorf L, Bittner M, Pretlow T, Elkahloun AG, Trepel JB, Kallioniemi O-P (2001) Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. Oncogene 20(46):6718\u20136723. https:\/\/doi.org\/10.1038\/sj.onc.1204889","journal-title":"Oncogene"},{"issue":"6320","key":"6168_CR32","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.aah4307","volume":"355","author":"P Mu","year":"2017","unstructured":"Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen C-C, Wongvipat J, Ku S-Y, Gao D, Cao Z, Shah N, Adams EJ, Abida W, Watson PA, Prandi D, Huang C-H, De Stanchina E, Lowe SW, Ellis L, Sawyers CL (2017) SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science 355(6320):84\u201388. https:\/\/doi.org\/10.1126\/science.aah4307","journal-title":"Science"},{"issue":"2","key":"6168_CR33","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1006\/geno.1997.4938","volume":"45","author":"J Nezu","year":"1997","unstructured":"Nezu J, Oku A, Jones MH, Shimane M (1997) Identification of two novel human putative serine\/threonine kinases, VRK1 and VRK2, with structural similarity to vaccinia virus B1R kinase. Genomics 45(2):327\u2013331. https:\/\/doi.org\/10.1006\/geno.1997.4938","journal-title":"Genomics"},{"issue":"9","key":"6168_CR34","doi-asserted-by":"publisher","first-page":"7934","DOI":"10.1074\/jbc.M310813200","volume":"279","author":"RJ Nichols","year":"2004","unstructured":"Nichols RJ, Traktman P (2004) Characterization of three paralogous members of the Mammalian vaccinia related kinase family. J Biol Chem 279(9):7934\u20137946. https:\/\/doi.org\/10.1074\/jbc.M310813200","journal-title":"J Biol Chem"},{"issue":"1","key":"6168_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","volume":"7","author":"RJ Rebello","year":"2021","unstructured":"Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van Der Kwast T, Bristow RG (2021) Prostate cancer. Nat Rev Dis Primers 7(1):9. https:\/\/doi.org\/10.1038\/s41572-020-00243-0","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"6168_CR36","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/15592294.2015.1028708","volume":"10","author":"M Salzano","year":"2015","unstructured":"Salzano M, Sanz-Garc\u00eda M, Monsalve DM, Moura DS, Lazo PA (2015) VRK1 chromatin kinase phosphorylates H2AX and is required for foci formation induced by DNA damage. Epigenetics 10(5):373\u2013383. https:\/\/doi.org\/10.1080\/15592294.2015.1028708","journal-title":"Epigenetics"},{"issue":"3","key":"6168_CR37","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1158\/1541-7786.MCR-05-0212","volume":"4","author":"CR Santos","year":"2006","unstructured":"Santos CR, Rodr\u00edguez-Pinilla M, Vega FM, Rodr\u00edguez-Peralto JL, Blanco S, Sevilla A, Valbuena A, Hern\u00e1ndez T, van Wijnen AJ, Li F, de Alava E, S\u00e1nchez-C\u00e9spedes M, Lazo PA (2006) VRK1 signaling pathway in the context of the proliferation phenotype in head and neck squamous cell carcinoma. Mol Cancer Res: MCR 4(3):177\u2013185. https:\/\/doi.org\/10.1158\/1541-7786.MCR-05-0212","journal-title":"Mol Cancer Res: MCR"},{"issue":"13","key":"6168_CR38","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin M-E, Sternberg CN, Miller K, De Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fl\u00e9chon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, De Bono JS (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367(13):1187\u20131197. https:\/\/doi.org\/10.1056\/NEJMoa1207506","journal-title":"N Engl J Med"},{"issue":"4","key":"6168_CR39","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.3892\/mmr.2015.4005","volume":"12","author":"X Sheng","year":"2015","unstructured":"Sheng X, Li W-B, Wang D-L, Chen K-H, Cao J-J, Luo Z, He J, Li M-C, Liu W-J, Yu C (2015) YAP is closely correlated with castration-resistant prostate cancer, and downregulation of YAP reduces proliferation and induces apoptosis of PC-3 cells. Mol Med Rep 12(4):4867\u20134876. https:\/\/doi.org\/10.3892\/mmr.2015.4005","journal-title":"Mol Med Rep"},{"issue":"1","key":"6168_CR40","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA: Cancer J Clin 74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820","journal-title":"CA: Cancer J Clin"},{"issue":"23","key":"6168_CR41","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","volume":"382","author":"CN Sternberg","year":"2020","unstructured":"Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, Ferreira U, Efstathiou E, Madziarska K, Kolinsky MP, Cubero DIG, Noerby B, Zohren F, Lin X, Modelska K, Sugg J, Steinberg J, Hussain M, Investigators PROSPER (2020) Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 382(23):2197\u20132206. https:\/\/doi.org\/10.1056\/NEJMoa2003892","journal-title":"N Engl J Med"},{"issue":"2","key":"6168_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001642","volume":"3","author":"A Valbuena","year":"2008","unstructured":"Valbuena A, L\u00f3pez-S\u00e1nchez I, Lazo PA (2008) Human VRK1 is an early response gene and its loss causes a block in cell cycle progression. PLoS ONE 3(2):e1642. https:\/\/doi.org\/10.1371\/journal.pone.0001642","journal-title":"PLoS ONE"},{"issue":"3","key":"6168_CR43","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.lungcan.2007.06.023","volume":"58","author":"A Valbuena","year":"2007","unstructured":"Valbuena A, Su\u00e1rez-Gauthier A, L\u00f3pez-Rios F, L\u00f3pez-Encuentra A, Blanco S, Fern\u00e1ndez PL, S\u00e1nchez-C\u00e9spedes M, Lazo PA (2007) Alteration of the VRK1-p53 autoregulatory loop in human lung carcinomas. Lung Cancer 58(3):303\u2013309. https:\/\/doi.org\/10.1016\/j.lungcan.2007.06.023","journal-title":"Lung Cancer"},{"issue":"12","key":"6168_CR44","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson PA, Arora VK, Sawyers CL (2015) Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer 15(12):701\u2013711. https:\/\/doi.org\/10.1038\/nrc4016","journal-title":"Nat Rev Cancer"},{"issue":"17","key":"6168_CR45","doi-asserted-by":"publisher","first-page":"4948","DOI":"10.1158\/0008-5472.CAN-16-0902","volume":"76","author":"S You","year":"2016","unstructured":"You S, Knudsen BS, Erho N, Alshalalfa M, Takhar M, Al-deen Ashab H, Davicioni E, Karnes RJ, Klein EA, Den RB, Ross AE, Schaeffer EM, Garraway IP, Kim J, Freeman MR (2016) Integrated classification of prostate cancer reveals a novel luminal subtype with poor outcome. Can Res 76(17):4948\u20134958. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-0902","journal-title":"Can Res"},{"issue":"6","key":"6168_CR46","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.ccell.2016.05.005","volume":"29","author":"F Zanconato","year":"2016","unstructured":"Zanconato F, Cordenonsi M, Piccolo S (2016) YAP\/TAZ at the roots of cancer. Cancer Cell 29(6):783\u2013803. https:\/\/doi.org\/10.1016\/j.ccell.2016.05.005","journal-title":"Cancer Cell"},{"issue":"1","key":"6168_CR47","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12894-024-01418-7","volume":"24","author":"C Zhou","year":"2024","unstructured":"Zhou C, Zhang X, Ma H, Zhou Y, Meng Y, Chen C, Shi G, Yu W, Zhang J (2024) USP54 is a potential therapeutic target in castration-resistant prostate cancer. BMC Urol 24(1):32. https:\/\/doi.org\/10.1186\/s12894-024-01418-7","journal-title":"BMC Urol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06168-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06168-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06168-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T14:25:22Z","timestamp":1744640722000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06168-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":47,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["6168"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06168-z","relation":{},"ISSN":["1432-1335"],"issn-type":[{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"assertion":[{"value":"8 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All animal procedures were approved by the Experimental Animal Ethics Committee of the Department of Laboratory Animal Science, Fudan University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"116"}}